Taken together, our data indicate that CUT-class homeobox genes CUX2 and ONECUT2 may be useful biomarkers while hypoxia factors EPAS1 and ARNT/ARNTL may serve as novel therapeutic targets for BPDCN (and ALCL). This evidence concerns the gene EPAS1 and anaplastic large cell lymphoma.